WooGene B&G Co. Ltd (018620) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of WooGene B&G Co. Ltd stock KRW 1,780, price KRW 2,650, that is 32.8% below the price, quality 47 out of 100. Rating: overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 2,245 KRW – 13,708 KRW · fair‑value band 1,173 KRW – 2,387 KRW · the 2,650 KRW price screens above the 1,780 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.
Follow WooGene B&G Co. in your weekly email
Every Wednesday you see whether WooGene B&G Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic.
Show moreShow less
It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001.
WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Seoul, South Korea.
Stock analysis
WooGene B&G Co. Ltd (018620) currently trades at 2,650 KRW, while our model-based Fair Value estimate is 1,780 KRW, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 1,907 KRW per share, and 1 of the 11 models we run sit above the 2,650 KRW price.
Bear case: the Asset-Based group reads lowest at 212.02 KRW, and 10 of the 11 models stay below the price. Data coverage for this calculation is low.
Scenario range: 1,173 KRW (bear) to 2,387 KRW (bull), the price of 2,650 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
WooGene B&G Co. Ltd reported revenue of 54.8B KRW in FY2025 versus 39.3B KRW in FY2021, a compound +8.6%/yr. Reported net income was −1.8B KRW in FY2025.
Key figures
Market cap 19.0B KRW (≈ $14.1M) Micro · P/S ratio 0.40 · Net margin −2.8% · Return on equity −1,661% · Return on assets (EBIT) −1.6% (5-year average) · Operating margin 2.8% · Revenue (TTM) 47.6B KRW · Revenue growth (YoY) +16.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −33%, 018620 screens richer than that median.
Fair Value models
Bear1,173 KRWFair Value 1,780 KRWBull2,387 KRW
Price 2,650 KRW · Downside -32.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic). Over 10 years: +8.8% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.7% (2020) → 0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +10.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−34.7% · Below median
Profitability
Return on assets−1.6% · Bottom 25%
Net margin (12 months)−2.8% · Bottom 25%
Operating margin (12 months)2.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)16.0% · Above median
Balance sheet
Debt / equity0.27× · Highest 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/B0.62× · Cheaper than median
P/S (12 months)0.40× · Cheapest 25%
Price / free cash flow (fiscal year)18.0× · Pricier than median
EV/EBITDA3.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)80· sector 51
PAST (return on equity)0· sector 15
HEALTH (low debt)87· sector 98
DIVIDEND (yield)0· sector 26
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is WooGene B&G Co. Ltd (018620) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 1,780 KRW versus a price of 2,650 KRW, about 33% lower (overvalued).
What is the fair value of 018620?
Our model-based fair value for WooGene B&G Co. Ltd is 1,780 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 2,650 KRW.
What is the quality score of 018620?
WooGene B&G Co. Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for WooGene B&G Co. Ltd (018620)?
Our model-based price target is the fair value of 1,780 KRW (as of Nov 5, 2026) from 11 valuation models. Cautious scenario 1,173 KRW, optimistic scenario 2,387 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the WooGene B&G Co. Ltd stock forecast for 2026?
Our models put fair value at 1,780 KRW, about 33% lower versus a price of 2,650 KRW (overvalued). Cautious scenario 1,173 KRW, optimistic scenario 2,387 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of WooGene B&G Co. Ltd (018620)?
WooGene B&G Co. Ltd reported trailing-twelve-month revenue of about 47.6B KRW (latest available figure, as of Nov 5, 2026).
What growth is priced into WooGene B&G Co. Ltd (018620)?
For today's price to be fair in a discounted-cash-flow model, WooGene B&G Co. Ltd would have to grow free cash flow by +13.0 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.7 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 018620 use?
Our models discount WooGene B&G Co. Ltd at 9.9 %: a base by market capitalisation (nano), damped by beta 0.89, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For WooGene B&G Co. Ltd that is +13.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has WooGene B&G Co. Ltd (018620) delivered so far?
Over the past 5 years revenue at WooGene B&G Co. Ltd grew +6.7 % a year. The price currently implies free-cash-flow growth of +13.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of WooGene B&G Co. Ltd (018620) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into WooGene B&G Co. Ltd (+13.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of WooGene B&G Co. Ltd (018620)?
The free-cash-flow yield on the price is 6.92 %: that much free cash flow WooGene B&G Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of WooGene B&G Co. Ltd (018620)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For WooGene B&G Co. Ltd it is 1,780 KRW per share (as of Nov 5, 2026), against a price of 2,650 KRW. It is the blended result of 11 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is WooGene B&G Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 018620 trades above its calculated fair value: price 2,650 KRW, fair value 1,780 KRW, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 018620?
No. The price is what the market pays today (2,650 KRW); the fair value is what the company's own numbers justify (1,780 KRW). For WooGene B&G Co. Ltd the two are 870.31 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is WooGene B&G Co. Ltd worth?
The market values WooGene B&G Co. Ltd at about 19.0B KRW (market capitalisation, as of Nov 5, 2026). Per share that is 2,650 KRW; our models calculate a fair value of 1,780 KRW per share.
What do the bullish and bearish scenarios say about 018620?
Our models span a range for WooGene B&G Co. Ltd: cautious scenario 1,173 KRW, base 1,780 KRW, optimistic 2,387 KRW per share (as of Nov 5, 2026, price 2,650 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of WooGene B&G Co. Ltd (018620)?
Balance-sheet figures for WooGene B&G Co. Ltd (as of Nov 5, 2026): debt of 0.27 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 018620 from its 52-week high?
WooGene B&G Co. Ltd trades at 2,650 KRW, about 29% below its 52-week high of 3,729 KRW and 18% above the low of 2,245 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 1,780 KRW is for.
Which stocks are comparable to WooGene B&G Co. Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is WooGene B&G Co. Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 2,650 KRW, calculated fair value 1,780 KRW (−33%), Quality Score 47/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 018620 calculated?
We run WooGene B&G Co. Ltd through 11 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of 1,780 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. WooGene B&G Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of WooGene B&G Co. Ltd (018620)?
The closing price on Nov 9, 2026 was 2,650 KRW. Our model-based fair value is 1,780 KRW, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with WooGene B&G Co. Ltd right now?
The price sits above even our optimistic bull case (2,387 KRW). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,173 KRW to 2,387 KRW) leaves room in how you read the outcome.
Key figures of WooGene B&G Co. Ltd
How large is the market capitalisation of WooGene B&G Co. Ltd (018620)?
The market capitalisation of WooGene B&G Co. Ltd is 19.0B KRW (≈ $14.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of WooGene B&G Co. Ltd (018620)?
The price-to-sales ratio of WooGene B&G Co. Ltd is 0.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of WooGene B&G Co. Ltd (018620)?
The net margin of WooGene B&G Co. Ltd is −2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of WooGene B&G Co. Ltd (018620)?
The return on equity (ROE) of WooGene B&G Co. Ltd is −1,661% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of WooGene B&G Co. Ltd (018620)?
On an EBIT basis the return on assets of WooGene B&G Co. Ltd is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of WooGene B&G Co. Ltd (018620)?
The operating margin of WooGene B&G Co. Ltd is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at WooGene B&G Co. Ltd (018620)?
Revenue at WooGene B&G Co. Ltd is growing +16.0% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does WooGene B&G Co. Ltd (018620) carry?
The net debt of WooGene B&G Co. Ltd is 16.8B KRW (fiscal year 2025, ≈ 15.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch WooGene B&G Co. Ltd in the live analysis
One click puts WooGene B&G Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026